Search

Search Constraints

You searched for: Author/Creator Plesner, Torben

Search Results

11. European Perspective on Multiple Myeloma Treatment Strategies in 2014. (25th July 2014)

12. European Perspective on Multiple Myeloma Treatment Strategies in 2014. (25th July 2014)

13. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR. Issue 10 (1st April 2021)

15. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Issue 7 (July 2016)

16. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. Issue 3 (20th January 2021)

17. Health‐related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial. (6th April 2021)

19. High‐Parameter Mass Cytometry Evaluation of Relapsed/Refractory Multiple Myeloma Patients Treated with Daratumumab Demonstrates Immune Modulation as a Novel Mechanism of Action. Issue 3 (11th December 2018)

20. Insights on Multiple Myeloma Treatment Strategies. Issue 1 (February 2019)